{
  "CitationSubset": [],
  "KeywordList": [
    [
      "COVID-19",
      "Convalescent plasma",
      "IVIG",
      "Plasma exchange"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32919880",
  "DateCompleted": {
    "Year": "2020",
    "Month": "12",
    "Day": "04"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "03",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "09",
        "Day": "05"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.transci.2020.102936",
      "S1473-0502(20)30252-4"
    ],
    "Journal": {
      "ISSN": "1473-0502",
      "JournalIssue": {
        "Volume": "59",
        "Issue": "5",
        "PubDate": {
          "Year": "2020",
          "Month": "Oct"
        }
      },
      "Title": "Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis",
      "ISOAbbreviation": "Transfus Apher Sci"
    },
    "ArticleTitle": "A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.",
    "Pagination": {
      "StartPage": "102936",
      "MedlinePgn": "102936"
    },
    "Abstract": {
      "AbstractText": [
        "The pathogenesis and immunopathological damage of severe forms of COVID-19 resemble acute autoimmune disease sparked by SARS-CoV-2, including an early systemic overproduction of proinflammatory cytokines. Such immunopathological features provide a rationale for the use of passive immunotherapy with convalescent plasma as a source of neutralizing anti-viral antibodies and of anti-inflammatory plasma components. While convalescent plasma therapy is now being evaluated in prospective clinical trials, we further consider the therapeutic potential of human hyper immune globulins, and of heterologous, engineered and monoclonal neutralizing antibodies as anti-viral agents to treat COVID-19. Good medical practice procedures are still needed and is why we also discuss the potential use of polyclonal polyspecific immunoglobulins (IVIG), a therapeutic plasma derivative, with potent anti-inflammatory activity, in severe forms of Covid-19."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020. Published by Elsevier Ltd."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein."
          }
        ],
        "LastName": "Lung",
        "ForeName": "Thomas",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Graduate Institute for International Affairs and Development, Geneva, Switzerland."
          }
        ],
        "LastName": "Kazatchkine",
        "ForeName": "Michel D",
        "Initials": "MD"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein."
          }
        ],
        "LastName": "Risch",
        "ForeName": "Lorenz",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein."
          }
        ],
        "LastName": "Risch",
        "ForeName": "Martin",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein. Electronic address: urs.nydegger@risch.ch."
          }
        ],
        "LastName": "Nydegger",
        "ForeName": "Urs E",
        "Initials": "UE"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Transfus Apher Sci",
    "NlmUniqueID": "101095653",
    "ISSNLinking": "1473-0502"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnosis",
        "immunology",
        "therapy"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Comorbidity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunization, Passive"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Plasma"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Serotherapy"
    }
  ]
}